Valby, Denmark, 19 February 2020 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 57,485 as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally DKK 5: 11,497 shares at DKK 113. Proceeds to the company are DKK 1,299,161 (approximately USD 0.192 million). The increase corresponds to approximately 0.0058 % of the company's share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company from the time of registration of the capital increase. The new shares will be listed on NASDAQ OMX Copenhagen after registration with the Danish Business Authority.
Lundbeck's current share capital amounts to DKK 995,683,625. The capital increase is expected to be finalized shortly, and the total number of voting rights and the total share capital will after this capital increase be:
Number of shares Nominal value Number of votes
(nominal value DKK of shares
199,148,222 995,741,110 199,148,222
Palle Holm Olesen
Vice President, Investor Relations
+45 30 83 24 26
Senior Director, Corporate Communication
+45 36 43 40 00
About H. Lundbeck A/S
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.
An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases - we call this Progress in Mind.
Read more at www.lundbeck.com/global/about-us/progress-in-mind (https://webmaster.lundbeck.com/N2/Content/wwww.lundbeck.com/global/about-us/progress-in-mind).
For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck and via LinkedIn.
Safe Harbor/Forward-Looking Statements
The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.
Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.
Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made considering past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.
H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
+45 3630 1311
(c) 2020 Cision. All rights reserved., source Press Releases - English